January 2018, Vol 172, No. 1, Pages 1-104
Improving the Study of New Medicines for Children With Rare Diseases
Florence T. Bourgeois, MD, MPH; Thomas J. Hwang, AB
JAMA Pediatr. 2018;172(1):7-9. doi:10.1001/jamapediatrics.2017.4012
This Viewpoint describes challenges in establishing guidelines for drugs to treat pediatric orphan diseases, and identifies legislative and administrative approaches to improvement.
Cost-effectiveness of Strategies for Offering Influenza Vaccine in the Pediatric Emergency Department
Rebecca J. Hart, MD; Michelle D. Stevenson, MD, MS; Michael J. Smith, MD, MSCE; et al.
JAMA Pediatr. 2018;172(1):e173879. doi:10.1001/jamapediatrics.2017.3879
This cost-effectiveness analysis compares 4 strategies for pediatric emergency department–based influenza vaccine: offering vaccine to all patients, only to patients younger than 5 years, only to high-risk patients (all ages), or to no patients.